Fecal lactoferrin early predicts long‐term outcomes in ulcerative colitis: A post‐hoc analysis of the UNIFI and PURSUIT trials
United European Gastroenterology Journal · 2023-07 · 11 (6) · 542-550
DOI: 10.1002/ueg2.12431 ↗Kurz gefasst
Fachartikel in der Zeitschrift United European Gastroenterology Journal, online erschienen am 23.06.2023. Verfasst von Rirong Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Guangdong Science and Technology Department, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Fecal lactoferrin (FL) is associated with disease activity and relapse in ulcerative colitis. However, whether FL could early predict long‐term outcomes in ulcerative colitis is poorly understood.
Methods
This post‐hoc analysis included participants who received biologics and had available data of FL concentration at week 4 from the UNIFI and PURSUIT trials ( n = 1063). Therapeutic outcomes, including clinical remission, endoscopic improvement and remission, and histological improvement and remission, were evaluated at the end of maintenance therapy. The incidence of colectomy was observed from week 0 to maximum week 228 in the PURSUIT trial ( n = 667). Multivariate logistic and Cox proportional‐hazard regression were conducted to evaluate the associations between FL and therapeutic outcomes and colectomy, respectively.
Results
A high FL level at week 4 was associated with poor long‐term clinical, endoscopic and histologic outcomes. FL >84.5 μg/mL predicted a low likelihood of clinical (OR [95% CI]: 0.43 [0.32, 0.57]; p < 0.001), endoscopic (OR [95% CI]: 0.40 [0.29, 0.56]; p < 0.001), and histological (OR [95% CI]: 0.27 [0.14, 0.53]; p < 0.001) remission. Moreover, week‐4 FL could add prognostic value to fecal calprotectin and clinical and endoscopic scores for informing long‐term therapeutic outcomes. For the risk of colectomy, patients with week‐4 FL
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China.
ORCID-Profile: Rirong Chen, Yizhe Tie, Li Li, Minhu Chen, Shenghong Zhang
Förderung
- Guangdong Science and Technology Department
- National Natural Science Foundation of China
Zitieren
APA
Chen, R., Tie, Y., Zhang, X., Li, L., Chen, M., & Zhang, S. (2023). Fecal lactoferrin early predicts long‐term outcomes in ulcerative colitis: A post‐hoc analysis of the UNIFI and PURSUIT trials. United European Gastroenterology Journal, 11(6), 542-550. https://doi.org/10.1002/ueg2.12431
Vancouver
Chen R, Tie Y, Zhang X, Li L, Chen M, Zhang S. Fecal lactoferrin early predicts long‐term outcomes in ulcerative colitis: A post‐hoc analysis of the UNIFI and PURSUIT trials. United European Gastroenterology Journal. 2023;11(6):542-550. doi:10.1002/ueg2.12431
BibTeX
@article{Chen2023,
author = {Chen, Rirong and Tie, Yizhe and Zhang, Xi and Li, Li and Chen, Minhu and Zhang, Shenghong},
title = {Fecal lactoferrin early predicts long‐term outcomes in ulcerative colitis: A post‐hoc analysis of the UNIFI and PURSUIT trials},
journal = {United European Gastroenterology Journal},
year = {2023},
volume = {11},
number = {6},
pages = {542--550},
doi = {10.1002/ueg2.12431}
}
EUVIMED